CD274 and head and neck squamous cell carcinoma: The INTERLINK-1 phase III study investigated the efficacy of cetuximab in combination with the NKG2A inhibitor monalizumab vs. cetuximab plus placebo in 624 human papilloma virus (HPV) unrelated R/M HNSCC patients, who were previously treated with a PD-(L)1 inhibitor and platinum chemotherapy.